Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

AL003

Other · developed by Alector

Phase 1 Most advanced trial (none active)

ALEC Developer

1 Registered trials

What is AL003?

AL003 is an agent studied in single-dose and multiple-dose cohorts in healthy participants and in Alzheimer disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Neurology
Developer: Alector Inc. (ALEC)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03822208	Phase 1	Healthy	Completed	ALEC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alzheimer DiseaseHealthy

More from Alector

AL002 Phase 2 GSK4527226 Phase 2 Osugacestat Phase 1

Sources

ClinicalTrials.gov NCT03822208

Updated Oct 11, 2026. Something wrong or missing? Report it on the ALEC page.

Follow ALEC, the company behind AL003

See ALEC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALEC catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z